Earnings Feed
Start Free
Home/Filings/4/0001209191-14-013779
4//SEC Filing

NUPATHE INC. 4

Accession 0001209191-14-013779

CIK 0001375200operating
View on SEC.govCompany Profile

Filed

Feb 24, 7:00 PM ET

Accepted

Feb 25, 11:57 AM ET

Size

43.9 KB

Accession

0001209191-14-013779

Insider Transaction Report

Form 4
Period: 2014-02-21
NUPATHE INC.PATH
Yetter Wayne P.
Director
Transactions
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21−7,486→ 0 total
    Exercise: $10.00Exp: 2020-08-05→ Common Stock (7,486 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21−6,750→ 0 total
    Exercise: $7.66Exp: 2021-06-08→ Common Stock (6,750 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21−1,072→ 0 total
    Exercise: $7.33Exp: 2021-06-30→ Common Stock (1,072 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.42/sh−823$2,815→ 0 total
    Exercise: $3.38Exp: 2022-12-31→ Common Stock (823 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.74/sh−923$3,452→ 0 total
    Exercise: $3.06Exp: 2023-06-30→ Common Stock (923 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$4.78/sh−4,001$19,125→ 0 total
    Exercise: $2.02Exp: 2021-09-30→ Common Stock (4,001 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.10/sh−733$2,272→ 0 total
    Exercise: $3.70Exp: 2022-03-31→ Common Stock (733 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.35/sh−668$2,238→ 0 total
    Exercise: $3.45Exp: 2023-03-31→ Common Stock (668 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21−1,000→ 0 total
    Exercise: $7.81Exp: 2021-03-31→ Common Stock (1,000 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$4.96/sh−4,401$21,829→ 0 total
    Exercise: $1.84Exp: 2021-12-30→ Common Stock (4,401 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.43/sh−6,750$23,153→ 0 total
    Exercise: $3.37Exp: 2022-06-07→ Common Stock (6,750 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$2.77/sh−637$1,764→ 0 total
    Exercise: $4.03Exp: 2022-06-30→ Common Stock (637 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.24/sh−730$2,365→ 0 total
    Exercise: $3.56Exp: 2022-09-30→ Common Stock (730 underlying)
  • Disposition to Issuer

    Common Stock

    2014-02-21$6.80/sh−13,500$91,800→ 0 total
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21−6,014→ 0 total
    Exercise: $7.75Exp: 2021-03-03→ Common Stock (6,014 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.81/sh−13,500$51,435→ 0 total
    Exercise: $2.99Exp: 2023-06-05→ Common Stock (13,500 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$4.39/sh−1,358$5,962→ 0 total
    Exercise: $2.41Exp: 2023-09-30→ Common Stock (1,358 underlying)
  • Disposition to Issuer

    Stock option (right to buy)

    2014-02-21$3.53/sh−1,002$3,537→ 0 total
    Exercise: $3.27Exp: 2023-12-31→ Common Stock (1,002 underlying)
Footnotes (4)
  • [F1]Includes all restricted stock units that became fully vested upon the consummation of the merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated January 17, 2014, among the issuer, Teva Pharmaceutical Industries Ltd. and Train Merger Sub, Inc.(the "Merger Agreement").
  • [F2]Disposed upon the consummation of the Merger in exchange for $3.65 per share, plus contractual rights to receive up to an additional $3.15 in contingent cash consideration payments per share.
  • [F3]Pursuant to the Merger Agreement, all options became fully vested upon the consummation of the Merger.
  • [F4]Pursuant to the Merger Agremeent, the option was converted into the right to receive, at the earliest date at which the sum of (1) the $3.65 per share cash portion of the merger consideration and (2) the amount per share in cash previously paid or to be paid at such date in connection with the Contingent Cash Consideration Agreement entered into in connection with the Merger Agreement (such sum, the "Per Share Paid Value") exceeds the per-share exercise price under the option: (x) an amount in cash equal to the number of shares of common stock subject to the option multiplied by the excess of (i) the then applicable Per Share Paid Value over (ii) the per-share exercise price under the option; and (y) the right to receive, in respect of each share of common stock subject to the option, each contingent cash consideration payment that, as of such date, has not yet become payable.

Documents

1 file

Issuer

NUPATHE INC.

CIK 0001375200

→
Entity typeoperating

Related Parties

1
  • filerCIK 0001375200

Filing Metadata

Form type
4
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 11:57 AM ET
Size
43.9 KB
View on SEC.gov